9.99
+3.52%
Close of 9 Nov 2026, in NOK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Circio Holding A
Its shares trade on Oslo Børs under the ticker CRNA.OL. It has been listed since 16 June 2014. In the fiscal year to 31 December 2025, it reported a net loss of NOK 45.9m. At that date it held total assets of NOK 10.8m and shareholders' equity of −NOK 12.5m.
Circio Holding ASA is a NO-based company operating in Biotechnology industry. The company is headquartered in Lysaker, Akershus. The company went IPO on 2014-06-16. Circio Holding ASA, formerly Targovax ASA, is a Norway-based company active within the healthcare sector. The firm is engaged in the biotechnology and develops ribonucleic acid (RNA) and immunotherapy medicines. The firm offers circular RNA (circRNA) platform to develop circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. Circios strategy is to develop circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate circRNA pipeline development. Circio’s second clinical program is an immunotherapy targeting KRAS driver mutations.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Jun 2014
- Employees
- 21
- Website
- circio.com/en ↗
Leadership
Pay as last reported
- Mr. Damian MarronChairman of the Board, since 2020
- Dr. Erik Digman WiklundChief Executive Officer
- Dr. Lubor GaalChief Financial Officer
- Mr. Jon EriksenChief Operating OfficerNOK 2.1m
- Mr. Antti VuolantoExecutive Vice PresidentNOK 2.0m
- Dr. Victor LevitskyChief Scientific Officer
- Ms. Anne AksnesVice President, Clinical DevelopmentNOK 1.3m
- Ms. Tina MadsenVice President, Quality AssuranceNOK 1.2m
- Mr. Peter SkorpilVice President, Business DevelopmentNOK 772,000
- Mr. Nikolaj KnudtzonHead of HR
- Mr. Magnus JaderbergChief Medical OfficerNOK 4.1m
- Mr. Ola MelinHead of Manufacturing
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Circio Holding ASA employs 21 full-time staff in Lysaker.
- The firm develops ribonucleic acid medicines for cancer treatment.
- The circVec technology enables efficient biogenesis of multifunctional circRNA.
Weaknesses
- The company has only 21 employees in the sector.
- Operations are limited to the Norway-based headquarters location.
- The firm went public on 16 June 2014 recently.
Opportunities
- Circio seeks partnerships in other therapeutic areas for growth.
- The platform can develop vaccines for genetic disorders.
- Circio’s second program targets KRAS driver mutations in therapy.
Threats
- The company operates in the competitive Biotechnology industry.
- Development of circRNA medicines faces regulatory scrutiny challenges.
- Reliance on in-house development may limit rapid expansion.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.